{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T16:40:19Z","timestamp":1786466419441,"version":"build-2736575974"},"reference-count":37,"publisher":"American Society of Hematology","issue":"15","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,8,11]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>Bruton tyrosine kinase inhibitors (BTKi) are successful in the treatment of chronic lymphocytic leukemia (CLL), yet acquired resistance remains a challenge. In our study, REC-1 cells that acquired resistance to the BTKi tirabrutinib by long-term treatment gained a splice site mutation (SSM) c.2236-1G&amp;gt;T in phospholipase C gamma 2 (PLCG2). Notably, a deletion spanning c.2236-23_2238 at the same splice site was identified in CLL from a patient who had disease progression during ibrutinib therapy. These alterations resulted in the exon-skipped variant \u039421, which exhibited enhanced phospholipase activity. PLCG2 SSM REC-1 exhibited increased anti\u2013immunoglobulin M\u2013mediated calcium flux and resistance to BTK inhibition but retained sensitivity to PLC\u03b3 inhibitors. By analyzing additional primary CLL samples, we identified widespread expression of 2 additional exon-skipped variants, \u039422 and \u039420-22, independent of PLCG2 genetic alterations. The active \u039420-22, which is also described in PLCG2-associated immune dysregulation, was predominantly present in CLL compared to healthy donor samples. Expression analysis in CLL cells isolated from patients before and after targeted treatments revealed a decrease in the expression of \u039420-22 after venetoclax treatment (P = .02), whereas no change in expression was observed after ibrutinib treatment, indicating that these variants may persist in the presence of ibrutinib but might be lost in the absence of drug selection pressure. Our study reveals novel PLCG2 splice site alterations and exon-skipped variants beyond the classical BTK or PLCG2 mutations to have a potential role in BTKi resistance and inform treatment selection.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/bloodadvances.2025019077","type":"journal-article","created":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T22:16:41Z","timestamp":1781043401000},"page":"5185-5198","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":0,"title":["<i>PLCG2<\/i>\n                    exon-skipped variants: insights into their potential role in chronic lymphocytic leukemia"],"prefix":"10.1182","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9168-2291","authenticated-orcid":false,"given":"Jialei","family":"Qi","sequence":"first","affiliation":[{"name":"1Division of Chronic Lymphocytic Leukaemia, Department of Internal Medicine III, Ulm University, Ulm, Germany"},{"name":"2Department of Hematology, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, Jiangsu, PR China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen","family":"Li","sequence":"additional","affiliation":[{"name":"1Division of Chronic Lymphocytic Leukaemia, Department of Internal Medicine III, Ulm University, Ulm, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rashmi Priyadharshini","family":"Dheenadayalan","sequence":"additional","affiliation":[{"name":"1Division of Chronic Lymphocytic Leukaemia, Department of Internal Medicine III, Ulm University, Ulm, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5473-4398","authenticated-orcid":false,"given":"Deyan Yordanov","family":"Yosifov","sequence":"additional","affiliation":[{"name":"1Division of Chronic Lymphocytic Leukaemia, Department of Internal Medicine III, Ulm University, Ulm, Germany"},{"name":"3Cooperation Unit \u201cMechanisms of Leukemogenesis,\u201d German Cancer Research Center, Heidelberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-5160-4732","authenticated-orcid":false,"given":"Cosima","family":"Drewes","sequence":"additional","affiliation":[{"name":"4Institute of Human Genetics, Ulm University, Ulm, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Wist","sequence":"additional","affiliation":[{"name":"5Institute of Experimental and Clinical Pharmacology, Toxicology and Pharmacology of Natural Products, Ulm University, Ulm, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcel","family":"Wieczorek","sequence":"additional","affiliation":[{"name":"1Division of Chronic Lymphocytic Leukaemia, Department of Internal Medicine III, Ulm University, Ulm, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vera","family":"Schmid","sequence":"additional","affiliation":[{"name":"6Institute of Immunology, Ulm University, Ulm, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elias","family":"Hobeika","sequence":"additional","affiliation":[{"name":"6Institute of Immunology, Ulm University, Ulm, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiang","family":"Gao","sequence":"additional","affiliation":[{"name":"7Department of Internal Medicine III, Ulm University, Ulm, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7243-6829","authenticated-orcid":false,"given":"Sascha","family":"Endres","sequence":"additional","affiliation":[{"name":"5Institute of Experimental and Clinical Pharmacology, Toxicology and Pharmacology of Natural Products, Ulm University, Ulm, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christof","family":"Schneider","sequence":"additional","affiliation":[{"name":"1Division of Chronic Lymphocytic Leukaemia, Department of Internal Medicine III, Ulm University, Ulm, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Armin","family":"Riecke","sequence":"additional","affiliation":[{"name":"1Division of Chronic Lymphocytic Leukaemia, Department of Internal Medicine III, Ulm University, Ulm, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2706-3402","authenticated-orcid":false,"given":"Holger","family":"Barth","sequence":"additional","affiliation":[{"name":"5Institute of Experimental and Clinical Pharmacology, Toxicology and Pharmacology of Natural Products, Ulm University, Ulm, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9295-5231","authenticated-orcid":false,"given":"Peter","family":"Gierschik","sequence":"additional","affiliation":[{"name":"5Institute of Experimental and Clinical Pharmacology, Toxicology and Pharmacology of Natural Products, Ulm University, Ulm, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reiner","family":"Siebert","sequence":"additional","affiliation":[{"name":"4Institute of Human Genetics, Ulm University, Ulm, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eugen","family":"Tausch","sequence":"additional","affiliation":[{"name":"1Division of Chronic Lymphocytic Leukaemia, Department of Internal Medicine III, Ulm University, Ulm, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephan","family":"Stilgenbauer","sequence":"additional","affiliation":[{"name":"1Division of Chronic Lymphocytic Leukaemia, Department of Internal Medicine III, Ulm University, Ulm, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6188-1652","authenticated-orcid":false,"given":"Billy Michael Chelliah","family":"Jebaraj","sequence":"additional","affiliation":[{"name":"1Division of Chronic Lymphocytic Leukaemia, Department of Internal Medicine III, Ulm University, Ulm, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2026,7,29]]},"reference":[{"issue":"12","key":"2026081110272602800_bib1","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1002\/ajh.26367","article-title":"Chronic lymphocytic leukemia: 2022 update on diagnostic and therapeutic procedures","volume":"96","author":"Hallek","year":"2021","journal-title":"Am J Hematol"},{"issue":"24","key":"2026081110272602800_bib2","doi-asserted-by":"crossref","first-page":"2286","DOI":"10.1056\/NEJMoa1400029","article-title":"Resistance mechanisms for the Bruton's tyrosine kinase inhibitor ibrutinib","volume":"370","author":"Woyach","year":"2014","journal-title":"N Engl J Med"},{"issue":"8","key":"2026081110272602800_bib3","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1056\/NEJMoa2114110","article-title":"Mechanisms of resistance to noncovalent Bruton's tyrosine kinase inhibitors","volume":"386","author":"Wang","year":"2022","journal-title":"N Engl J Med"},{"issue":"19","key":"2026081110272602800_bib4","doi-asserted-by":"crossref","first-page":"5698","DOI":"10.1182\/bloodadvances.2022008955","article-title":"Acquired BTK mutations associated with resistance to noncovalent BTK inhibitors","volume":"7","author":"Qi","year":"2023","journal-title":"Blood Adv"},{"issue":"1","key":"2026081110272602800_bib5","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1182\/blood-2015-02-626846","article-title":"Hypermorphic mutation of phospholipase C, \u03b32 acquired in ibrutinib-resistant CLL confers BTK independency upon B-cell receptor activation","volume":"126","author":"Liu","year":"2015","journal-title":"Blood"},{"issue":"42","key":"2026081110272602800_bib6","doi-asserted-by":"crossref","first-page":"22136","DOI":"10.1074\/jbc.M116.746842","article-title":"The phospholipase C\u03b32 mutants R665W and L845F identified in ibrutinib-resistant chronic lymphocytic leukemia patients are hypersensitive to the Rho GTPase Rac2 Protein","volume":"291","author":"Walliser","year":"2016","journal-title":"J Biol Chem"},{"issue":"8","key":"2026081110272602800_bib7","doi-asserted-by":"crossref","first-page":"1918","DOI":"10.1182\/bloodadvances.2024014206","article-title":"Acquired mutations in patients with relapsed\/refractory CLL who progressed in the ALPINE study","volume":"9","author":"Brown","year":"2025","journal-title":"Blood Adv"},{"issue":"10","key":"2026081110272602800_bib8","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1182\/blood.2023023659","article-title":"Mutational profile in previously treated patients with chronic lymphocytic leukemia progression on acalabrutinib or ibrutinib","volume":"144","author":"Woyach","year":"2024","journal-title":"Blood"},{"issue":"3","key":"2026081110272602800_bib9","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1038\/s41568-022-00541-7","article-title":"RNA splicing dysregulation and the hallmarks of cancer","volume":"23","author":"Bradley","year":"2023","journal-title":"Nat Rev Cancer"},{"issue":"8","key":"2026081110272602800_bib10","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1182\/blood.2019004260","article-title":"Splicing factor mutations in hematologic malignancies","volume":"138","author":"Chen","year":"2021","journal-title":"Blood"},{"issue":"3","key":"2026081110272602800_bib11","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1158\/2643-3230.BCD-22-0156","article-title":"METTL3-mediated m6A modification controls splicing factor abundance and contributes to aggressive CLL","volume":"4","author":"Wu","year":"2023","journal-title":"Blood Cancer Discov"},{"issue":"7","key":"2026081110272602800_bib12","doi-asserted-by":"crossref","first-page":"2327","DOI":"10.1182\/blood.V93.7.2327","article-title":"An alternatively spliced form of CD79b gene may account for altered B-cell receptor expression in B-chronic lymphocytic leukemia","volume":"93","author":"Alfarano","year":"1999","journal-title":"Blood"},{"issue":"7","key":"2026081110272602800_bib13","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1097\/PAT.0b013e32835a0142","article-title":"Differential expression of the Bcl-2 and Bax isoforms in CD19 positive B-lymphocytes isolated from patients diagnosed with chronic lymphocytic leukaemia","volume":"44","author":"Ghassemifar","year":"2012","journal-title":"Pathology"},{"issue":"12","key":"2026081110272602800_bib14","doi-asserted-by":"crossref","first-page":"3125","DOI":"10.3324\/haematol.2020.261891","article-title":"SF3B1-mutated chronic lymphocytic leukemia shows evidence of NOTCH1 pathway activation including CD20 downregulation","volume":"106","author":"Pozzo","year":"2020","journal-title":"Haematol"},{"issue":"5","key":"2026081110272602800_bib15","doi-asserted-by":"crossref","first-page":"159627","DOI":"10.1016\/j.bbalip.2025.159627","article-title":"Phosphoinositide-specific phospholipase C enzymes: recent advances in a long journey","volume":"1870","author":"Macrae","year":"2025","journal-title":"Biochim Biophys Acta Mol Cell Biol Lipids"},{"issue":"4","key":"2026081110272602800_bib16","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1056\/NEJMoa1102140","article-title":"Cold urticaria, immunodeficiency, and autoimmunity related to PLCG2 deletions","volume":"366","author":"Ombrello","year":"2012","journal-title":"N Engl J Med"},{"issue":"3","key":"2026081110272602800_bib17","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaci.2024.06.025","article-title":"Splice site and de novo variants can cause PLCG2-associated immune dysregulation with cold urticaria","volume":"155","author":"Chou","year":"2025","journal-title":"J Allergy Clin Immunol"},{"issue":"76","key":"2026081110272602800_bib18","doi-asserted-by":"crossref","first-page":"34357","DOI":"10.18632\/oncotarget.26173","article-title":"Functional characterization of phospholipase C- \u03b32 mutant protein causing both somatic ibrutinib resistance and a germline monogenic autoinflammatory disorder","volume":"9","author":"Walliser","year":"2018","journal-title":"Oncotarget"},{"issue":"9","key":"2026081110272602800_bib19","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1016\/j.cellsig.2016.05.010","article-title":"Cool-temperature-mediated activation of phospholipase C-\u03b32 in the human hereditary disease PLAID","volume":"28","author":"Schade","year":"2016","journal-title":"Cell Signal"},{"issue":"1","key":"2026081110272602800_bib20","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1093\/bioinformatics\/bts635","article-title":"STAR: ultrafast universal RNA-seq aligner","volume":"29","author":"Dobin","year":"2013","journal-title":"Bioinformatics"},{"issue":"2","key":"2026081110272602800_bib21","doi-asserted-by":"crossref","first-page":"gkaf018","DOI":"10.1093\/nar\/gkaf018","article-title":"edgeR v4: powerful differential analysis of sequencing data with expanded functionality and improved support for small counts and larger datasets","volume":"53","author":"Chen","year":"2025","journal-title":"Nucleic Acids Res"},{"key":"2026081110272602800_bib22","unstructured":"Kolde\n              R\n            \n          . pheatmap: Pretty Heatmaps. Accessed 12 June 2026. https:\/\/github.com\/raivokolde\/pheatmap."},{"issue":"11","key":"2026081110272602800_bib23","doi-asserted-by":"crossref","first-page":"3292","DOI":"10.1038\/s41596-024-01020-z","article-title":"Using clusterProfiler to characterize multiomics data","volume":"19","author":"Xu","year":"2024","journal-title":"Nat Protoc"},{"key":"2026081110272602800_bib24","author":"Wickham","year":"2016"},{"key":"2026081110272602800_bib25","unstructured":"G Y. Enrichplot\n          . Visualization of Functional Enrichment Result. Accessed 12 June 2026. https:\/\/yulab-smu.top\/biomedical-knowledge-mining-book\/."},{"issue":"44","key":"2026081110272602800_bib26","doi-asserted-by":"crossref","first-page":"30351","DOI":"10.1074\/jbc.M803316200","article-title":"Rac regulates its effector phospholipase Cgamma2 through interaction with a split pleckstrin homology domain","volume":"283","author":"Walliser","year":"2008","journal-title":"J Biol Chem"},{"key":"2026081110272602800_bib27","doi-asserted-by":"crossref","first-page":"e77809","DOI":"10.7554\/eLife.77809","article-title":"Dynamics of allosteric regulation of the phospholipase C-\u03b3 isozymes upon recruitment to membranes","volume":"11","author":"Siraliev-Perez","year":"2022","journal-title":"Elife"},{"issue":"22","key":"2026081110272602800_bib28","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1182\/blood.2023020142","article-title":"EGR1-mediated metabolic reprogramming to oxidative phosphorylation contributes to ibrutinib resistance in B-cell lymphoma","volume":"142","author":"Liu","year":"2023","journal-title":"Blood"},{"issue":"1","key":"2026081110272602800_bib29","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1038\/s41467-025-56318-7","article-title":"Longitudinal omics data and preclinical treatment suggest the proteasome inhibitor carfilzomib as therapy for ibrutinib-resistant CLL","volume":"16","author":"Arseni","year":"2025","journal-title":"Nat Commun"},{"issue":"1","key":"2026081110272602800_bib30","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1038\/s41392-024-01757-9","article-title":"NF-\u03baB in biology and targeted therapy: new insights and translational implications","volume":"9","author":"Guo","year":"2024","journal-title":"Signal Transduct Target Ther"},{"issue":"8","key":"2026081110272602800_bib31","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1038\/nri3487","article-title":"New insights into pre-BCR and BCR signalling with relevance to B cell malignancies","volume":"13","author":"Rickert","year":"2013","journal-title":"Nat Rev Immunol"},{"issue":"4","key":"2026081110272602800_bib32","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1038\/s41419-023-05755-7","article-title":"PLCG2 can exist in eccDNA and contribute to the metastasis of non-small cell lung cancer by regulating mitochondrial respiration","volume":"14","author":"Yang","year":"2023","journal-title":"Cell Death Dis"},{"issue":"10277","key":"2026081110272602800_bib33","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1016\/S0140-6736(21)00224-5","article-title":"Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1\/2 study","volume":"397","author":"Mato","year":"2021","journal-title":"Lancet"},{"issue":"4","key":"2026081110272602800_bib34","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1056\/NEJMoa2211582","article-title":"Zanubrutinib or ibrutinib in relapsed or refractory chronic lymphocytic leukemia","volume":"388","author":"Brown","year":"2023","journal-title":"N Engl J Med"},{"issue":"6682","key":"2026081110272602800_bib35","doi-asserted-by":"crossref","first-page":"eadi5798","DOI":"10.1126\/science.adi5798","article-title":"Kinase-impaired BTK mutations are susceptible to clinical-stage BTK and IKZF1\/3 degrader NX-2127","volume":"383","author":"Montoya","year":"2024","journal-title":"Science"},{"key":"2026081110272602800_bib36","doi-asserted-by":"crossref","first-page":"101053","DOI":"10.1016\/j.jbior.2024.101053","article-title":"Characterisation of molecular mechanisms for PLC\u03b32 disease-linked variants","volume":"94","author":"Bunney","year":"2024","journal-title":"Adv Biol Regul"},{"issue":"12","key":"2026081110272602800_bib37","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1182\/bloodadvances.2016003632","article-title":"Clonal evolution underlying leukemia progression and Richter transformation in patients with ibrutinib-relapsed CLL","volume":"1","author":"Kadri","year":"2017","journal-title":"Blood Adv"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/15\/5185\/2535610\/blooda_adv-2025-019077-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/15\/5185\/2535610\/blooda_adv-2025-019077-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T15:43:41Z","timestamp":1786463021000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/10\/15\/5185\/568885\/PLCG2-exon-skipped-variants-insights-into-their"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,29]]},"references-count":37,"journal-issue":{"issue":"15","published-print":{"date-parts":[[2026,8,11]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2025019077","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,8,11]]},"published":{"date-parts":[[2026,7,29]]}}}